ArticleFuture medicinal chemistry2009
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Article in Future medicinal chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.British journal of clinical pharmacology · 2012Trial
- Nitriles: an attractive approach to the development of covalent inhibitors.RSC medicinal chemistry · 2023Review
- Mesenchymal stem cells: amazing remedies for bone and cartilage defects.Stem cell research & therapy · 2020Review
- Function of Cathepsin K in the Central Nervous System of Male Mice is Independent of Its Role in the Thyroid Gland.Cellular and molecular neurobiology · 2020Article
- Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management.Cancers · 2019Review
- The Osteoclast in Bone Metastasis: Player and Target.Cancers · 2018Review
- Role of odanacatib in reducing bone loss due to endodontic disease: An overview.Journal of International Society of Preventive & Community Dentistry · 2016Review
- Photoactivated inhibition of cathepsin K in a 3D tumor model.Biological chemistry · 2016Article
- Training differentially regulates elastin level and proteolysis in skeletal and heart muscles and aorta in healthy rats.Biology open · 2016Article
- Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors.Progress in medicinal chemistry · 2016Review
- Molecular dynamics simulation of halogen bonding mimics experimental data for cathepsin L inhibition.Journal of computer-aided molecular design · 2015Article
- Structural basis of collagen fiber degradation by cathepsin K.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Inhibition of cathepsin activity in a cell-based assay by a light-activated ruthenium compound.ChemMedChem · 2014Article
- Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.Therapeutic advances in musculoskeletal disease · 2013Article
- Article
- Effects of cathepsin K deficiency on intercellular junction proteins, luminal mucus layers, and extracellular matrix constituents in the mouse colon.Biological chemistry · 2012Article
- Potential role of odanacatib in the treatment of osteoporosis.Clinical interventions in aging · 2012Review
- Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.BoneKEy reports · 2012Article
- Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits.BMC neuroscience · 2011Article
- Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.Nature reviews. Rheumatology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundUntil fairly recently, cathepsin K was recognized solely as a bone-resorbing enzyme expressed selectively in the osteoclast. Evidence of its requirement for normal bone remodeling has resulted in this protease receiving considerable attention from the pharmaceutical industry. In the last decade, intense research efforts were aimed at development of cathepsin K inhibitors for treatment of osteoporosis and other skeletal disorders associated with pathological bone loss. Emerging new evidence suggests that in addition to bone resorption, cathepsin K is involved in the turnover of extracellular matrix proteins in organs, such as the lung, thyroid and skin, and plays important roles in cardiovascular disease, inflammation and obesity. DISCUSSION: This review highlights the physiological and pathophysiological implications of this potent protease, with a focus on recent developments in the design and use of cathepsin K inhibitors to target skeletal pathologies. Therapeutic implications of anticathepsin K drugs in the context of common links between bone disease and atherosclerosis are also discussed.
conclusionThe association of cathepsin K with skeletal and cardiovascular disorders offers intriguing future applications for inhibitors of this potent protease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.